MRD, Remission Independent Prognostic Factors for AML

Article

In patients with AML, post-therapy parameters including minimal residual disease and remission were found to be independent prognostic factors for outcomes.

Bone marrow aspirate showing AML

Bone marrow aspirate showing AML. Image source: Tontoni, Wikimedia Commons.

In patients with acute myeloid leukemia (AML), post-therapy parameters including minimal residual disease (MRD) status were found to be independent prognostic factors for outcomes, according to the results of a retrospective study published recently in the Journal of Clinical Oncology.

According to the study, many commonly assessed patient covariates have limited predictive value for AML. Instead, researchers have begun to evaluate information gained after treatment, such as response to therapy, to estimate risk for relapse and survival.

In this study, Xueyan Chen, MD, PhD, of the University of Washington, and colleagues evaluated the relationship between MRD and clinical response, such as complete remission (CR), CR with incomplete platelet recovery (CRp), and CR with incomplete blood count recovery (Cri) to determine if these parameters had independent effects on outcomes for patients with AML.

“Our study seems to be the first to demonstrate a significant correlation between MRD and response; patients who achieved [CR] with incomplete blood count recovery (CRp or CRi) more frequently had MRD and higher levels of MRD than patients achieving CR,” wrote Chen and colleagues. “This finding suggests that failure of blood count recovery may result from inadequate treatment of AML, as well as the more commonly assumed toxicity to normal progenitors.”

The researchers looked at data from 245 adults with AML who achieved CR, CRp, or CRi; 165 patients had newly diagnosed disease and 80 had relapsed or refractory disease. Seventy-one percent of patients achieved a CR, 19.6% achieved CRp, and 9.4% achieved CRi.

Data indicated that the 71% of patients who achieved CR had MRD less frequently and had lower levels of MRD than patients achieving CRp and CRi (0.5% vs 1.1% vs 2.7%).

“Although monosomal karyotype, FLT3 ITD mutation, and relapsed or refractory AML are assumed to be associated with greater risk of relapse, whereas favorable cytogenetics are assumed to be associated with a reduced risk of relapse, and were found to be so in our univariable analyses, these factors lost much of their significance once MRD and response were taken into account,” the researchers wrote.  

This finding indicates that any risk assessment done at diagnosis of multiple myeloma should be adjusted to take into account post-therapy data. Specifically, CR, CRp, and CRi are all independent prognostic factors for relapse, overall survival, and recurrence-free survival in AML.

“Information about these post-treatment factors is likely more important than information about several traditional pretreatment prognostic factors and should play a major-and perhaps the dominant-role in planning postinduction therapy,” the researchers wrote.

Recent Videos
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Related Content